Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs

Kohei Miyaji, Hiroshi Tada, Kengo Fukushima Kusano, Tohru Hashimoto, Kenichi Kaseno, Shigeki Hiramatsu, Kazuyoshi Tadokoro, Shigeto Naito, Kazufumi Nakamura, Shigeru Oshima, Koichi Taniguchi, Tohru Ohe

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Bepridil has multiple ion-channel blocking effects and is expected to be useful for managing atrial fibrillation (AF). The purpose of this study was to clarify the efficacy and safety of additional treatment with bepridil in patients with AF who had been treated with class I antiarrhythmic drugs (AADs). Methods and Results: Bepridil (50-200 mg/day) was given to 76 patients with either paroxysmal (n=49) or persistent AF (n=27). All patients had been treated with class I AADs (1.9±0.9 drugs/patient) that failed to control the AF. With the addition of bepridil, the frequency of symptomatic AF episodes decreased to less than 10% in 38 (78%) patients with paroxysmal AF, and sinus rhythm was restored within 3 months and maintained during the follow-up in 20 (74%) patients with persistent AF. Efficacy was usually obtained with a small to moderate dose (50-150 mg/day) of bepridil. During a mean follow-up period of 27±22 months, no potential complications occurred in any of the patients. Conclusions: The addition of bepridil to class I AADs is effective and safe for AF, but careful observation using periodic ECG recordings is essential for avoiding torsades de pointes caused by QT prolongation.

Original languageEnglish
Pages (from-to)1250-1257
Number of pages8
JournalCirculation Journal
Volume71
Issue number8
DOIs
Publication statusPublished - 2007

Fingerprint

Bepridil
Anti-Arrhythmia Agents
Atrial Fibrillation
Safety
Therapeutics
Torsades de Pointes
Ion Channels
Electrocardiography
Observation

Keywords

  • Antiarrhythmic drugs
  • Atrial fibrillation
  • Bepridil

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology

Cite this

Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. / Miyaji, Kohei; Tada, Hiroshi; Kusano, Kengo Fukushima; Hashimoto, Tohru; Kaseno, Kenichi; Hiramatsu, Shigeki; Tadokoro, Kazuyoshi; Naito, Shigeto; Nakamura, Kazufumi; Oshima, Shigeru; Taniguchi, Koichi; Ohe, Tohru.

In: Circulation Journal, Vol. 71, No. 8, 2007, p. 1250-1257.

Research output: Contribution to journalArticle

Miyaji, K, Tada, H, Kusano, KF, Hashimoto, T, Kaseno, K, Hiramatsu, S, Tadokoro, K, Naito, S, Nakamura, K, Oshima, S, Taniguchi, K & Ohe, T 2007, 'Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs', Circulation Journal, vol. 71, no. 8, pp. 1250-1257. https://doi.org/10.1253/circj.71.1250
Miyaji, Kohei ; Tada, Hiroshi ; Kusano, Kengo Fukushima ; Hashimoto, Tohru ; Kaseno, Kenichi ; Hiramatsu, Shigeki ; Tadokoro, Kazuyoshi ; Naito, Shigeto ; Nakamura, Kazufumi ; Oshima, Shigeru ; Taniguchi, Koichi ; Ohe, Tohru. / Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. In: Circulation Journal. 2007 ; Vol. 71, No. 8. pp. 1250-1257.
@article{891cd2ab903c4048b6286068f9a60788,
title = "Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs",
abstract = "Background: Bepridil has multiple ion-channel blocking effects and is expected to be useful for managing atrial fibrillation (AF). The purpose of this study was to clarify the efficacy and safety of additional treatment with bepridil in patients with AF who had been treated with class I antiarrhythmic drugs (AADs). Methods and Results: Bepridil (50-200 mg/day) was given to 76 patients with either paroxysmal (n=49) or persistent AF (n=27). All patients had been treated with class I AADs (1.9±0.9 drugs/patient) that failed to control the AF. With the addition of bepridil, the frequency of symptomatic AF episodes decreased to less than 10{\%} in 38 (78{\%}) patients with paroxysmal AF, and sinus rhythm was restored within 3 months and maintained during the follow-up in 20 (74{\%}) patients with persistent AF. Efficacy was usually obtained with a small to moderate dose (50-150 mg/day) of bepridil. During a mean follow-up period of 27±22 months, no potential complications occurred in any of the patients. Conclusions: The addition of bepridil to class I AADs is effective and safe for AF, but careful observation using periodic ECG recordings is essential for avoiding torsades de pointes caused by QT prolongation.",
keywords = "Antiarrhythmic drugs, Atrial fibrillation, Bepridil",
author = "Kohei Miyaji and Hiroshi Tada and Kusano, {Kengo Fukushima} and Tohru Hashimoto and Kenichi Kaseno and Shigeki Hiramatsu and Kazuyoshi Tadokoro and Shigeto Naito and Kazufumi Nakamura and Shigeru Oshima and Koichi Taniguchi and Tohru Ohe",
year = "2007",
doi = "10.1253/circj.71.1250",
language = "English",
volume = "71",
pages = "1250--1257",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "8",

}

TY - JOUR

T1 - Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs

AU - Miyaji, Kohei

AU - Tada, Hiroshi

AU - Kusano, Kengo Fukushima

AU - Hashimoto, Tohru

AU - Kaseno, Kenichi

AU - Hiramatsu, Shigeki

AU - Tadokoro, Kazuyoshi

AU - Naito, Shigeto

AU - Nakamura, Kazufumi

AU - Oshima, Shigeru

AU - Taniguchi, Koichi

AU - Ohe, Tohru

PY - 2007

Y1 - 2007

N2 - Background: Bepridil has multiple ion-channel blocking effects and is expected to be useful for managing atrial fibrillation (AF). The purpose of this study was to clarify the efficacy and safety of additional treatment with bepridil in patients with AF who had been treated with class I antiarrhythmic drugs (AADs). Methods and Results: Bepridil (50-200 mg/day) was given to 76 patients with either paroxysmal (n=49) or persistent AF (n=27). All patients had been treated with class I AADs (1.9±0.9 drugs/patient) that failed to control the AF. With the addition of bepridil, the frequency of symptomatic AF episodes decreased to less than 10% in 38 (78%) patients with paroxysmal AF, and sinus rhythm was restored within 3 months and maintained during the follow-up in 20 (74%) patients with persistent AF. Efficacy was usually obtained with a small to moderate dose (50-150 mg/day) of bepridil. During a mean follow-up period of 27±22 months, no potential complications occurred in any of the patients. Conclusions: The addition of bepridil to class I AADs is effective and safe for AF, but careful observation using periodic ECG recordings is essential for avoiding torsades de pointes caused by QT prolongation.

AB - Background: Bepridil has multiple ion-channel blocking effects and is expected to be useful for managing atrial fibrillation (AF). The purpose of this study was to clarify the efficacy and safety of additional treatment with bepridil in patients with AF who had been treated with class I antiarrhythmic drugs (AADs). Methods and Results: Bepridil (50-200 mg/day) was given to 76 patients with either paroxysmal (n=49) or persistent AF (n=27). All patients had been treated with class I AADs (1.9±0.9 drugs/patient) that failed to control the AF. With the addition of bepridil, the frequency of symptomatic AF episodes decreased to less than 10% in 38 (78%) patients with paroxysmal AF, and sinus rhythm was restored within 3 months and maintained during the follow-up in 20 (74%) patients with persistent AF. Efficacy was usually obtained with a small to moderate dose (50-150 mg/day) of bepridil. During a mean follow-up period of 27±22 months, no potential complications occurred in any of the patients. Conclusions: The addition of bepridil to class I AADs is effective and safe for AF, but careful observation using periodic ECG recordings is essential for avoiding torsades de pointes caused by QT prolongation.

KW - Antiarrhythmic drugs

KW - Atrial fibrillation

KW - Bepridil

UR - http://www.scopus.com/inward/record.url?scp=34547575590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547575590&partnerID=8YFLogxK

U2 - 10.1253/circj.71.1250

DO - 10.1253/circj.71.1250

M3 - Article

C2 - 17652890

AN - SCOPUS:34547575590

VL - 71

SP - 1250

EP - 1257

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 8

ER -